The Oncology Podcast

Send us Fan Mail
S4E5 The Oncology Journal Club Podcast 

The Oncology Journal Club team returns with Part 2 of its ASCO 2026 coverage, delivering a whirlwind tour through some of the most interesting studies presented across gastrointestinal, breast, lung, genitourinary, gynaecological, skin and haematological cancers.
Craig Underhill, Kate Clarke and Christopher Jackson discuss emerging data on ctDNA-guided treatment strategies, exercise as adjuvant therapy, genomic testing in breast cancer, novel antibody-drug conjugates, immunotherapy advances, de-escalation studies and potential new standards of care. They also explore the growing role of precision medicine, evolving treatment sequencing strategies and the challenges facing the global oncology workforce.
Along the way, expect the usual OJC banter, ASCO bingo, questionable drug pronunciations and a recurring tribute to Qantas pyjamas!
The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Send us Fan Mail
S4E4 The Oncology Journal Club Podcast 
In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting’s most talked-about studies and discuss what they could mean for clinical practice.
From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.
The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.
Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.
The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

Send us Fan Mail
In this episode of The Oncology Journal Club, the team cover one of the most talked-about pancreatic cancer papers of the year, unpacking the promising early results for daraxonrasib in previously treated RAS-mutated pancreatic cancer and the science behind new RAS(ON) therapeutics. 
The team also discuss a fascinating phase II study of single-cycle neoadjuvant pembrolizumab in MMR-deficient colon cancer, new recommendations from the Prostate Cancer Working Group 4 and why the terminology we use in prostate cancer matters.
Along the way, there’s discussion of Bob Marley’s acral melanoma, multidisciplinary lung cancer meetings, androgen receptor-positive TNBC, HER2-mutant lung cancer and whether oxybutynin could help men experiencing androgen deprivation-related hot flushes.
The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.

Send us Fan Mail
Proudly Produced by The Oncology Network
Professor Craig Underhill and Rachael Babin break down the key oncology changes from the May 2026 PBS update.
This month we run through 3 fresh PBS listings that affect Australian oncology and haematology practice, from fruquintinib, a late-line colorectal cancer treatment, through to new haematology options.  
Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail
In this episode of The Oncology Journal Club, the team weigh promising trial signals against the level of evidence needed to change clinical practice. From perioperative cholangiocarcinoma to molecular matching and chrono-oncology, the focus stays on a key question: what meaningfully improves outcomes for patients?
What’s covered
 NeoGOLP trial in high-risk resectable iCCA: improved event-free survival; overall survival still immature 
 MoST programme: molecular matching and survival associations when therapies align with biomarkers 
 Genomic therapy matching in clinical decision-making 
 Chrono-oncology: does treatment timing influence outcomes? 
 CHOPIN phase II uveal melanoma trial: combination therapy signals and feasibility 
 ASCO living guideline updates across lung, gastro-oesophageal and thyroid cancers 
The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.